Will Agenus Inc (NASDAQ:AGEN) Run Out of Steam Soon? Short Interest is Up

April 17, 2018 - By Richard Conner

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment decreased to 1.26 in Q4 2017. Its down 0.08, from 1.34 in 2017Q3. It worsened, as 12 investors sold Agenus Inc. shares while 27 reduced holdings. 24 funds opened positions while 25 raised stakes. 36.32 million shares or 1.74% less from 36.96 million shares in 2017Q3 were reported.
Moreover, Artal Gru has 0.12% invested in Agenus Inc. (NASDAQ:AGEN) for 2.50 million shares. Swiss Fincl Bank reported 149,200 shares. Millennium Mgmt Ltd Llc owns 2.49M shares or 0.01% of their US portfolio. 52,513 are owned by National Bank Of America De. Vident Investment Advisory Llc holds 0.05% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 354,696 shares. Balyasny Asset Mgmt Lc has 28,762 shares for 0% of their portfolio. Stifel Corp reported 0% stake. Badgley Phelps & Bell invested in 33,000 shares. Credit Suisse Ag holds 0% in Agenus Inc. (NASDAQ:AGEN) or 60,860 shares. 613,619 are owned by D E Shaw. Legal General Grp Inc Public Limited Company reported 19,812 shares. Wells Fargo Mn reported 449,307 shares or 0% of all its holdings. Sei Invs accumulated 2,666 shares or 0% of the stock. Ingalls & Snyder Lc owns 14,700 shares. Metropolitan Life Insurance Ny holds 0% or 22,950 shares in its portfolio.

The stock of Agenus Inc (NASDAQ:AGEN) registered an increase of 4.39% in short interest. AGEN’s total short interest was 10.74M shares in April as published by FINRA. Its up 4.39% from 10.29M shares, reported previously. With 1.81M shares average volume, it will take short sellers 6 days to cover their AGEN’s short positions. The short interest to Agenus Inc’s float is 13.64%.

The stock decreased 1.70% or $0.07 during the last trading session, reaching $4.04. About 1.02M shares traded. Agenus Inc. (NASDAQ:AGEN) has risen 19.90% since April 17, 2017 and is uptrending. It has outperformed by 8.35% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $414.33 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: